StockNews.com Upgrades Omeros (NASDAQ:OMER) to Hold

Omeros (NASDAQ:OMERGet Free Report) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a report released on Sunday.

Separately, Cantor Fitzgerald downgraded shares of Omeros from an “overweight” rating to a “neutral” rating in a research report on Friday, November 10th.

Get Our Latest Research Report on OMER

Omeros Stock Up 2.5 %

Omeros stock opened at $3.92 on Friday. The company has a fifty day simple moving average of $3.29 and a 200 day simple moving average of $2.89. Omeros has a 1-year low of $0.92 and a 1-year high of $7.80. The company has a market cap of $246.14 million, a P/E ratio of 12.23 and a beta of 1.30. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 10.80.

Insider Activity

In other news, CEO Gregory A. Md Demopulos acquired 15,000 shares of the firm’s stock in a transaction dated Friday, November 17th. The stock was bought at an average price of $1.68 per share, with a total value of $25,200.00. Following the transaction, the chief executive officer now directly owns 123,945 shares in the company, valued at approximately $208,227.60. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 10.90% of the company’s stock.

Institutional Trading of Omeros

Hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. acquired a new stake in shares of Omeros during the 2nd quarter worth about $27,000. Farther Finance Advisors LLC acquired a new stake in shares of Omeros during the 2nd quarter worth about $33,000. ExodusPoint Capital Management LP acquired a new stake in shares of Omeros during the 1st quarter worth about $54,000. Alliancebernstein L.P. acquired a new stake in Omeros in the 2nd quarter worth about $64,000. Finally, ProShare Advisors LLC acquired a new stake in Omeros in the 2nd quarter worth about $65,000. Institutional investors and hedge funds own 41.70% of the company’s stock.

Omeros Company Profile

(Get Free Report)

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

Further Reading

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.